Specialty Pharmacy

Discovery may lead to significant new HIV treatments.

Recent advances and updates in oncology and cancer drug development.

ONC201 caused p53-independent cell death and cell cycle arrest in lymphoma and acute leukemia patient samples.

Despite progress in legalizing medical marijuana, incorporating it into clinical trials for epilepsy to prevent seizures remains difficult.

Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences.

Ibrutinib (Imbruvica) is the first chemotherapy-free treatment for first line CLL patients approved by the FDA.

Study found no standalone Medicare Part D plans covered vaccinations without out-of-pocket payments.

The latest Magellan Health report highlights spending trends and current pharmacy benefit issues.

Dan Steiber, Editor in Chief for Specialty Pharmacy Times, discusses limited distribution and other pressing issues impacting the specialty pharmacy landscape in a recent podcast.

Ocrelizumab shows promise reducing symptoms of MS.

Ocrelizumab selectively targets CD20+B cells to reduce disease activity in patients with primary progressive multiple sclerosis.

Most read articles of the week on Specialty Pharmacy Times.

Nearly half of patients required 10 or more office visits before receiving a Crohn's disease diagnosis.

Blincyto is currently the only FDA-approved bispecific CD19-directed CD3 T cell engager immunotherapy available for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL.

Researchers examine acceptance rates and factors predicting doctor acceptance of pharmacist recommendations within a Medicare Advantage Plan.

BioMarin's AAV 5 factor VIII vector restores FVIII plasma concentrations, which are essential for creating blood clots in hemophilia A patients.

Researchers examine the risk of cancer recurrence among inflammatory bowel disease patients who take anti-TNF therapy.

Children of mothers who took atazanavir showed slightly decreased scores on language and social-emotional development.

Durvalumab and tremelimumab was active in patients with or without tumor expression of PD-L1 in NSCLC.

Telehealth offers a support system for patients with specific chronic illnesses prone to exacerbations and remissions, such as COPD.

Monitoring tool can help fight fraud, safeguard taxpayer dollars, and protect beneficiaries.

Nanoparticles acting as cancer drug delivery vehicles show promise in eliminating tumors.

Medication spending waste can be reduced with smaller vials of cancer drugs, study finds.

High cost infused cancer drugs are packaged containing quantities larger than needed to treat patients.

Improvements seek to promote continuity in the Marketplace with a goal of ensuring that health care coverage is accessible and affordable to consumers.

Odefsey can be used as a replacement for antiretroviral therapy in HIV-positive patients who are virologically-suppressed.

Odefsey is the smallest single tablet regimen to treat patients 12-years-old and above infected with HIV.

This case is the first reported failure for pre-exposure prophylaxis to stop HIV infection.